Carregant...

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antiviral Res
Autors principals: Caly, Leon, Druce, Julian D., Catton, Mike G., Jans, David A., Wagstaff, Kylie M.
Format: Artigo
Idioma:Inglês
Publicat: The Author(s). Published by Elsevier B.V. 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7129059/
https://ncbi.nlm.nih.gov/pubmed/32251768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2020.104787
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!